Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARCT NASDAQ:BLTE NASDAQ:IBRX NASDAQ:IDYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$19.68-7.2%$17.64$8.04▼$23.59$534.41M2.39516,305 shs1.04 million shsBLTEBelite Bio$78.50+0.6%$68.61$49.00▼$86.53$2.50B-1.4645,483 shs73,499 shsIBRXImmunityBio$2.44-3.6%$2.49$1.83▼$7.48$2.31B0.278.22 million shs12.69 million shsIDYAIDEAYA Biosciences$26.79-0.2%$25.16$13.45▼$32.67$2.35B0.141.16 million shs1.48 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics+3.57%+3.52%+18.83%+46.41%-5.65%BLTEBelite Bio+0.85%+6.20%+15.63%+25.84%+44.77%IBRXImmunityBio+1.20%+2.02%+4.98%-11.85%-28.13%IDYAIDEAYA Biosciences-0.30%-1.90%+14.75%+17.72%-13.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$19.68-7.2%$17.64$8.04▼$23.59$534.41M2.39516,305 shs1.04 million shsBLTEBelite Bio$78.50+0.6%$68.61$49.00▼$86.53$2.50B-1.4645,483 shs73,499 shsIBRXImmunityBio$2.44-3.6%$2.49$1.83▼$7.48$2.31B0.278.22 million shs12.69 million shsIDYAIDEAYA Biosciences$26.79-0.2%$25.16$13.45▼$32.67$2.35B0.141.16 million shs1.48 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics+3.57%+3.52%+18.83%+46.41%-5.65%BLTEBelite Bio+0.85%+6.20%+15.63%+25.84%+44.77%IBRXImmunityBio+1.20%+2.02%+4.98%-11.85%-28.13%IDYAIDEAYA Biosciences-0.30%-1.90%+14.75%+17.72%-13.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics 2.78Moderate Buy$50.57141.97% UpsideBLTEBelite Bio 2.50Moderate Buy$96.0022.18% UpsideIBRXImmunityBio 2.83Moderate Buy$10.75345.13% UpsideIDYAIDEAYA Biosciences 2.72Moderate Buy$43.3660.75% UpsideCurrent Analyst Ratings BreakdownLatest ARCT, IDYA, BLTE, and IBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ARCTArcturus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025BLTEBelite BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025IDYAIDEAYA BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ARCTArcturus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025BLTEBelite BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025IBRXImmunityBioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025IDYAIDEAYA BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/18/2025IDYAIDEAYA BiosciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.009/16/2025BLTEBelite BioZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/15/2025BLTEBelite BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$100.00 ➝ $98.009/12/2025IDYAIDEAYA BiosciencesMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$43.00 ➝ $44.00(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$109.80M5.17N/AN/A$8.90 per share2.35BLTEBelite BioN/AN/AN/AN/A$4.72 per shareN/AIBRXImmunityBio$14.74M154.87N/AN/A($0.57) per share-4.24IDYAIDEAYA Biosciences$7M337.69N/AN/A$12.25 per share2.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$80.94M-$2.23N/AN/AN/A-49.26%-24.87%-17.75%11/6/2025 (Estimated)BLTEBelite Bio-$36.14M-$1.55N/AN/AN/AN/A-34.90%-33.56%11/11/2025 (Estimated)IBRXImmunityBio-$413.56M-$0.48N/AN/AN/A-648.57%N/A-113.86%11/11/2025 (Estimated)IDYAIDEAYA Biosciences-$274.48M-$3.79N/AN/AN/AN/A-31.42%-29.45%11/3/2025 (Estimated)Latest ARCT, IDYA, BLTE, and IBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025ARCTArcturus Therapeutics-$1.09N/AN/AN/A$17.47 millionN/A11/3/2025Q3 2025IDYAIDEAYA Biosciences-$0.12N/AN/AN/A$59.98 millionN/A8/11/2025Q2 2025ARCTArcturus Therapeutics-$1.11-$0.34+$0.77-$0.34$17.64 million$28.30 million8/11/2025Q2 2025BLTEBelite Bio-$0.47-$0.50-$0.03-$0.50N/AN/A8/5/2025Q2 2025IBRXImmunityBio-$0.10-$0.10N/A-$0.10$21.95 million$26.43 million8/5/2025Q2 2025IDYAIDEAYA Biosciences-$0.85-$0.88-$0.03-$0.88$3.48 million$6.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus Therapeutics$0.713.42%N/AN/A N/ABLTEBelite BioN/AN/AN/AN/AN/AIBRXImmunityBioN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus TherapeuticsN/A5.905.90BLTEBelite BioN/A23.1523.15IBRXImmunityBioN/A4.113.98IDYAIDEAYA BiosciencesN/A12.3912.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%BLTEBelite Bio0.53%IBRXImmunityBio8.58%IDYAIDEAYA Biosciences98.29%Insider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics16.60%BLTEBelite Bio13.29%IBRXImmunityBio76.79%IDYAIDEAYA Biosciences2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18027.16 million22.65 millionOptionableBLTEBelite Bio1031.84 million27.61 millionNot OptionableIBRXImmunityBio590945.26 million219.39 millionOptionableIDYAIDEAYA Biosciences8087.64 million85.45 millionOptionableARCT, IDYA, BLTE, and IBRX HeadlinesRecent News About These CompaniesIDEAYA Biosciences' (IDYA) "Sell (D-)" Rating Reiterated at Weiss RatingsOctober 9 at 4:26 AM | marketbeat.comJ.P. Morgan Remains Bullish on IDEAYA Biosciences (IDYA)October 8 at 5:29 AM | msn.comWall Street Zen Upgrades IDEAYA Biosciences (NASDAQ:IDYA) to HoldOctober 5, 2025 | americanbankingnews.comIDEAYA Biosciences (NASDAQ:IDYA) Stock Rating Upgraded by Wall Street ZenOctober 3, 2025 | marketbeat.comPlatinum Investment Management Ltd. Has $3.51 Million Stake in IDEAYA Biosciences, Inc. $IDYAOctober 2, 2025 | marketbeat.comIDEAYA Biosciences Earns Relative Strength Rating Upgrade; Hits Key BenchmarkSeptember 30, 2025 | msn.comVoya Investment Management LLC Has $377,000 Stock Position in IDEAYA Biosciences, Inc. $IDYASeptember 28, 2025 | marketbeat.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 26, 2025 | prnewswire.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 24, 2025 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Coverage Initiated by Analysts at GuggenheimSeptember 19, 2025 | marketbeat.comGuggenheim Initiates Coverage of IDEAYA Biosciences (IDYA) with Buy RecommendationSeptember 19, 2025 | msn.comRhumbline Advisers Boosts Stock Position in IDEAYA Biosciences, Inc. $IDYASeptember 18, 2025 | marketbeat.comIdeaya Biosciences initiated with a Buy at GuggenheimSeptember 17, 2025 | msn.comWoodline Partners LP Has $5.17 Million Position in IDEAYA Biosciences, Inc. $IDYASeptember 15, 2025 | marketbeat.comMizuho Boosts IDEAYA Biosciences (NASDAQ:IDYA) Price Target to $44.00September 14, 2025 | marketbeat.comMizuho Securities Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)September 13, 2025 | theglobeandmail.comCould IDEAYA Biosciences' (IDYA) Expanding Pipeline Redefine Its Long-Term Value Proposition?September 13, 2025 | finance.yahoo.comLeerink Partnrs Has Negative Outlook of IDYA FY2026 EarningsSeptember 13, 2025 | marketbeat.comIdeaya Biosciences price target raised to $44 from $43 at MizuhoSeptember 12, 2025 | msn.comIDEAYA Biosciences (NASDAQ:IDYA) Trading 5.6% Higher Following Analyst UpgradeSeptember 11, 2025 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Price Target Raised to $38.00 at Royal Bank Of CanadaSeptember 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARCT, IDYA, BLTE, and IBRX Company DescriptionsArcturus Therapeutics NASDAQ:ARCT$19.68 -1.52 (-7.17%) Closing price 04:00 PM EasternExtended Trading$20.05 +0.37 (+1.85%) As of 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Belite Bio NASDAQ:BLTE$78.50 +0.44 (+0.56%) Closing price 04:00 PM EasternExtended Trading$78.32 -0.17 (-0.22%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.ImmunityBio NASDAQ:IBRX$2.44 -0.09 (-3.56%) Closing price 04:00 PM EasternExtended Trading$2.44 +0.00 (+0.20%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.IDEAYA Biosciences NASDAQ:IDYA$26.79 -0.05 (-0.19%) Closing price 04:00 PM EasternExtended Trading$26.53 -0.26 (-0.99%) As of 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
